The effect of pilocarpine on dental caries in patients with primary Sjögren’s syndrome: a database prospective cohort study
Autor: | Chung-Yuan Hsu, Yu-Sheng Lin, Chun Yu Lin, Ming-Shyan Lin, Ying Chou Chen, Chi Hua Ko, Tien Hsing Chen, Kuo Chun Hung |
---|---|
Rok vydání: | 2019 |
Předmět: |
Adult
Male medicine.medical_specialty Saliva lcsh:Diseases of the musculoskeletal system Taiwan Primary Sjögren’s syndrome Muscarinic Agonists 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine Outcome Assessment Health Care medicine Clinical endpoint Humans Prospective Studies Registries Periodontitis Propensity Score Prospective cohort study 030203 arthritis & rheumatology Proportional hazards model business.industry Hazard ratio Candidiasis Pilocarpine 030206 dentistry Middle Aged medicine.disease Confidence interval stomatognathic diseases Sjogren's Syndrome Dental caries Female lcsh:RC925-935 business Research Article medicine.drug |
Zdroj: | Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-10 (2019) Arthritis Research & Therapy |
ISSN: | 1478-6362 |
Popis: | Background Primary Sjögren’s syndrome (pSS) is associated with dental caries. Pilocarpine, a salivary stimulant, can improve the amount and flow rate of saliva in patients with pSS. This study aimed to assess whether the risk of dental caries decreases with the use of pilocarpine in patients with pSS. Methods For this prospective cohort study, we identified pSS patients from the catastrophic illnesses registry of the National Health Insurance Research Database of Taiwan between 2009 and 2013. We divided participants into pilocarpine and non-user groups based on the pilocarpine prescriptions available during the first 3-month follow-up. The primary endpoint was dental caries. The secondary endpoints were periodontitis and oral candidiasis. We compared the risk of these oral manifestations using the Cox proportional hazard model. Results A total of 4973 patients with new-onset pSS were eligible for analysis. After propensity score matching, we included 1014 patients in the pilocarpine group and 2028 patients in the non-user group. During the mean follow-up of 2.6 years, the number of events was 487 in the pilocarpine group (48.0%) and 1047 in the non-user group (51.6%); however, the difference was not significant (hazard ratio [HR] 0.93, 95% confidence interval [CI] 0.82 to 1.06). Furthermore, there was no significant difference between groups regarding risk of periodontitis (HR 0.91, 95% CI 0.81 to 1.03) and oral candidiasis (HR 1.16, 95% CI 0.70 to 1.94). Conclusion Pilocarpine may have no protective effect on dental caries, periodontitis, or oral candidiasis in patients with pSS. |
Databáze: | OpenAIRE |
Externí odkaz: |